A substantially larger median NT-proBNP decrease was shown with empagliflozin than with placebo among patients who were hospitalised with an acute big MI when empagliflozin was started early and administered in addition to the post-MI care suggested by guidelines. This evidence concerns the gene NPPB and myocardial infarction.